Policy & Regulation
Nimble Therapeutics, Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics
15 September 2021 - - US-based biotechnology company Nimble Therapeutics' strategic research collaboration with US-based pharmaceutical company Incyte (NASDAQ: INCY) has been expanded to include discovery of additional novel peptide therapies.

Under the terms of the agreement, Nimble will receive an upfront payment and reimbursement of certain research program costs and may become eligible for downstream milestone payments and royalties.

Incyte has exclusive rights to develop and commercialize any peptides discovered under the collaboration and has an option to further expand the collaboration to include additional targets.

Nimble Therapeutics is a biotechnology company dedicated to delivering on the promise of peptide therapeutics.